Document ID: L_3_05
Section: L_Genetics_Origins
Keywords: blood type, ABO system, Rh factor, Karl Landsteiner, blood transfusion, blood group antigens, glycosyltransferase, agglutination, Rh disease, hemolytic disease of newborn, Bombay phenotype, Duffy, MNS, Kell, Lewis, blood group evolution, malaria selection, forensic serology, universal donor, population genetics
Category Tags: genetics, human-origins, evolution, medicine-healing
Cross-References: L_2_02 — Population Genetics · Z_2_04 — Genetic Disorders · Z_1_04 — Gene Expression Regulation · R_1_12 — History of Evolutionary Theory · L_4_02 — Mendel Inheritance
Reliability Tier: Tier 1 (established immunogenetics)
Last Updated: Mar 9, 2026 | Source Count: 12 | Weighted Score: 31 | Source Confidence: [4/5] | Confidence: High

QUICK SUMMARY

Blood group genetics represents one of the earliest and most clinically important applications of Mendelian inheritance in human biology. Karl Landsteiner's discovery of the ABO blood group system (1900–1901) — which earned the Nobel Prize in Physiology or Medicine (1930) — revolutionized transfusion medicine by explaining why some blood transfusions caused fatal hemolytic reactions while others succeeded. The ABO system is determined by a single gene on chromosome 9 (9q34.2) encoding a glycosyltransferase enzyme that adds sugar residues to the H antigen on red blood cell surfaces: the A allele adds N-acetylgalactosamine (→ A antigen), the B allele adds galactose (→ B antigen), and the O allele is a loss-of-function variant (single nucleotide deletion → frameshift → no functional enzyme → H antigen unmodified). A and B are codominant to each other and both dominant over O, producing six genotypes and four phenotypes (A, B, AB, O). Individuals naturally produce antibodies against the ABO antigens they lack — anti-B in type A individuals, anti-A in type B, both in type O, neither in type AB — making ABO compatibility the primary requirement for safe blood transfusion. The Rh (Rhesus) system, the second most important clinically, centers on the RhD protein (encoded by RHD gene, chromosome 1); Rh-negative mothers carrying Rh-positive fetuses risk alloimmunization, causing hemolytic disease of the fetus and newborn (HDFN) in subsequent pregnancies — largely preventable since 1968 with anti-D immunoglobulin (RhoGAM). Over 360 blood group antigens across 43 systems have been identified (ISBT classification, 2023), many with clinical significance in transfusion, transplantation, and obstetrics. Population frequency variation in blood groups reflects evolutionary forces, particularly balancing selection and pathogen-driven selection — the Duffy-negative phenotype (FY\O), nearly universal in sub-Saharan Africa, confers resistance to Plasmodium vivax* malaria, representing one of the strongest known signals of natural selection in the human genome.

1. VERIFIED CLAIMS (Tier 1 — Peer-Reviewed / Established)

1.1 ABO Blood Group System

• Discovery (1900–1901): Karl Landsteiner mixed sera and red blood cells from colleagues; observed agglutination patterns → three groups initially (A, B, C/O); fourth group (AB) identified by Decastello and Sturli (1902); Nobel Prize 1930; enabled safe blood transfusion
• Genetics: Single gene (ABO) on chromosome 9q34.2; encodes glycosyltransferase; three main alleles: A (N-acetylgalactosamine transferase), B (galactose transferase), O (nonfunctional — single nucleotide deletion at position 261 causes frameshift); A and B codominant; both dominant over O; six genotypes (AA, AO, BB, BO, AB, OO) → four phenotypes
• H antigen: Precursor structure (fucose added to precursor chain by FUT1 gene product); ABO gene modifies H antigen; Bombay phenotype (Oh): homozygous FUT1 loss-of-function → no H antigen → no substrate for A or B enzymes → phenotypically appears type O but cannot receive type O blood (has anti-H antibodies); extremely rare (~1/10,000 in Mumbai, much rarer elsewhere)
• Antibodies: "Natural" IgM antibodies against missing ABO antigens appear in first months of life, likely stimulated by environmental antigens (gut bacteria carbohydrates); anti-A and anti-B can cause acute hemolytic transfusion reactions → intravascular hemolysis, renal failure, death; ABO matching is mandatory for transfusion
• Subgroups: A₁ (~80% of type A) and A₂ (~20%) are clinically important subtypes; A₂ produces less A antigen; ~1–8% of A₂ and A₂B individuals develop anti-A₁ antibodies; over 200 ABO alleles cataloged

1.2 Rh Blood Group System

• Rh antigens: Encoded by RHD and RHCE genes on chromosome 1p36.11 (tandem arrangment, >97% sequence homology); RhD protein = most immunogenic blood group antigen after ABO; 50 defined Rh antigens; clinically important: D, C, c, E, e
• Rh-negative phenotype: Deletion of RHD gene (most common mechanism in Europeans); ~15% of European populations are Rh-negative (dd); much rarer in East Asian (<1%) and African populations (~3–5%, though Africans often have RHD pseudogene or hybrid RHD-CE-D rather than gene deletion)
• Hemolytic disease of the fetus and newborn (HDFN): Rh-negative mother exposed to Rh-positive fetal red blood cells (typically during delivery) → produces anti-D IgG antibodies → in subsequent Rh-positive pregnancy, maternal IgG crosses placenta → destroys fetal red cells → fetal anemia, hydrops fetalis, kernicterus (bilirubin encephalopathy); historically caused significant perinatal mortality
• Prevention with anti-D immunoglobulin (RhoGAM, 1968): Injection of anti-D antibody to Rh-negative mothers at 28 weeks and within 72 hours of delivery → prevents maternal sensitization; one of medicine's great preventive interventions; reduced HDFN from ~14% to <0.1% of Rh-negative pregnancies; developed simultaneously by Columbia (Gruenberg, Gruenwald) and Ortho groups

1.3 Other Clinically Important Blood Group Systems

• Kell system: KEL antigen highly immunogenic (second after D in clinical significance for HDFN); McLeod syndrome — X-linked XK gene mutations → absent Kx antigen → acanthocytosis, neurological disease
• Duffy system (FY): DARC/ACKR1 gene, chromosome 1q23.2; Duffy antigen is receptor for Plasmodium vivax merozoite invasion; Duffy-negative (FY\O) individuals resistant to P. vivax malaria; FY\O = GATA-1 binding site mutation in promoter → no erythrocyte expression; frequency ~100% in West Africa, absent in non-African populations → one of the clearest examples of natural selection in human genome
• MNS system (glycophorins A and B): Plasmodium falciparum uses glycophorin for erythrocyte invasion; structural variants (Dantu, GYPB-A hybrid) associated with malaria resistance in East Africa
• Lewis and Secretor systems: FUT2 (secretor gene) determines whether ABO antigens expressed in saliva and mucosal surfaces; ~20% of Europeans are non-secretors; Helicobacter pylori binding preferences linked to Lewis/Secretor status and gastric disease susceptibility

2. CREDIBLE CLAIMS (Tier 2 — Strong Evidence, Active Research)

2.1 ABO and Disease Associations

• Type O: Slightly increased risk of peptic ulcer, cholera severity; decreased risk of cardiovascular thrombosis (lower von Willebrand factor levels — VWF clearance is faster); type O individuals have ~25% lower VWF and FVIII levels
• Type A: Increased risk of gastric cancer (OR ~1.2), venous thromboembolism; H. pylori strain-specific interactions with A/B antigens affect gastric colonization
• COVID-19 association: Multiple GWAS identified 9q34 (ABO locus) as significantly associated with COVID-19 severity; type O associated with slightly reduced risk, type A with increased risk; mechanism debated (antibody-mediated neutralization? endothelial VWF levels? ACE2 interactions?)
• Pathogen selection: ABO polymorphism maintained by balancing selection, likely pathogen-driven; different pathogens selectively disadvantage different blood types → no single allele universally favored; explains maintenance of polymorphism across human populations despite different frequencies

2.2 Blood Group Genomics and Population History

• Population frequency variation: Type O highest in Indigenous Americans (>90% in some groups) and Indigenous Australians; type B highest in Central Asia (~30–40%); European populations: A ~40%, O ~45%, B ~10%, AB ~5%; global frequency patterns shaped by drift, founder effects, and selection
• Molecular dating: ABO polymorphism predates human speciation — A and B alleles found in other great apes (chimpanzees, gorillas, gibbons) via trans-species polymorphism; ABO gene diversification estimated at 5–20 million years; maintained by balancing selection across speciation events

2.3 "Universal Donor" and "Universal Recipient" Are Context-Dependent Labels

• The familiar shorthand that O negative is a universal donor and AB positive is a universal recipient applies most cleanly to emergency red-cell transfusion, not to every blood product or every clinical circumstance
• Plasma compatibility runs in the opposite direction from red-cell compatibility, platelet transfusion can be complicated by ABO mismatch, and non-ABO antigens such as Rh, Kell, Kidd, and Duffy still matter in chronically transfused patients and pregnancy care
• This is why modern transfusion medicine treats ABO as foundational but not sufficient: the safe product depends on whether the patient is receiving red cells, plasma, platelets, or repeated antigen exposure over time

3. SPECULATIVE CLAIMS (Tier 3 — Emerging / Theoretical)

3.1 Blood Type and Gut Microbiome

• ABO antigens expressed on intestinal mucosa influence microbial colonization; secretor status (FUT2) affects gut microbiome composition and susceptibility to norovirus infection (non-secretors protected against GI.1 and GII.4 strains); emerging evidence that blood type may influence metabolic health via microbiome-mediated pathways; mechanisms still being characterized

3.2 Enzymatic Blood Type Conversion

• Bacterial enzymes can remove A and B antigens from red blood cells, converting them to "universal" O-type; Rahfeld et al. (2019) identified gut bacterial enzymes (from Flavonifractor plautii) highly efficient at cleaving A antigen; could address universal donor shortage; clinical trials ongoing as of 2025; scalability and cost remain challenges

4. DUBIOUS CLAIMS (Tier 4 — Fringe / Unsubstantiated)

4.1 Blood Type Diet [NO EVIDENCE]

• Peter D'Adamo's "Eat Right 4 Your Type" (1996) claims each blood type requires specific diet based on evolutionary history (O = "hunter" diet [high protein], A = "agrarian" [vegetarian], etc.); no scientific evidence supports personalized nutrition by blood type; systematic review (Cusack et al., 2013) and large prospective study (Wang et al., 2014) found no support; premise of blood-type-specific lectins causing disease is biochemically unsound

4.2 Blood Type and Personality [NO EVIDENCE]

• Popular in Japan and South Korea — "ketsueki-gata" theory that blood type determines personality traits (Type A = organized, Type B = creative, Type O = confident, Type AB = unpredictable); no scientific basis; multiple large studies (~10,000+ participants) find no correlation between ABO type and personality traits; cultural phenomenon without biological support

IMAGES

Counter-Arguments & Criticisms

No significant counter-arguments exist in the scholarly literature for the core claims presented here. The topic of Blood Type Genetics ABO System represents established knowledge within genetics, DNA, and human origins with no active scholarly dispute over the fundamental claims presented in this document.

BIBLIOGRAPHY

1. Landsteiner, K. . , 14, 1132 1134 | 1901 | "Über Agglutinationserscheinungen normalen menschlichen Blutes" | Wiener Klinische Wochenschrift | ∅ | ∅ | ∅ | ∅ | ∅ | ∅ | ∅ | ∅
2. Yamamoto, F. et al. . , 345, 229 233 | 1990 | "Molecular Genetic Basis of the Histo-Blood Group ABO System" | Nature | ∅ | ∅ | ∅ | ∅ | doi:10.1038/345229a0 | ∅ | ∅ | ∅
3. Daniels, G. . . | 2013 | ∅ | Human Blood Groups | ∅ | ∅ | Wiley-Blackwell | 3rd | isbn:9781444333244 | ∅ | ∅ | ∅
4. Bowman, J | 2003 | "Rh Immunoglobulin: Rh Prophylaxis" | Best Practice & Research Clinical Haematology | ∅ | ∅ | M. . , 16(1), 97 109 | ∅ | ∅ | ∅ | ∅ | ∅
5. Miller, L | 1976 | "The Resistance Factor to Plasmodium vivax in Blacks: The Duffy-Blood-Group Genotype, FyFy" | New England Journal of Medicine | ∅ | ∅ | H. et al. . , 295, 302 304 | ∅ | doi:10.1056/NEJM197608052950602 | ∅ | ∅ | ∅
6. Cusack, L., De Buck, E., Compernolle, V.; Vandekerckhove, P. . , 98(1), 99 104 | 2013 | "Blood Type Diets Lack Supporting Evidence: A Systematic Review" | American Journal of Clinical Nutrition | ∅ | ∅ | ∅ | ∅ | doi:10.3945/ajcn.113.058693 | ∅ | ∅ | ∅
7. Ellinghaus, D. et al. . , 383, 1522 1534 | 2020 | "Genomewide Association Study of Severe Covid-19 with Respiratory Failure" | New England Journal of Medicine | ∅ | ∅ | ∅ | ∅ | doi:10.1056/NEJMoa2020283 | ∅ | ∅ | ∅
8. Rahfeld, P. et al. . , 4, 1475 1485 | 2019 | "An Enzymatic Pathway in the Human Gut Microbiome That Converts A to Universal O Type Blood" | Nature Microbiology | ∅ | ∅ | ∅ | ∅ | doi:10.1038/s41564-019-0469-7 | ∅ | ∅ | ∅
9. Storry, J | 2023 | "International Society of Blood Transfusion Working Party on Red Cell Immunogenetics and Blood Group Terminology" | Vox Sanguinis | ∅ | ∅ | R. et al. . , 118(5), 373 392 | ∅ | doi:10.1111/vox.13447 | ∅ | ∅ | ∅
10. Ségurel, L. et al. . , 109(45), 18493 18498 | 2012 | "The ABO Blood Group Is a Trans-Species Polymorphism in Primates" | Proceedings of the National Academy of Sciences | ∅ | ∅ | ∅ | ∅ | doi:10.1073/pnas.1210603109 | ∅ | ∅ | ∅
11. Cooling, L. . , 28(3), 801 870 | 2015 | "Blood Groups in Infection and Host Susceptibility" | Clinical Microbiology Reviews | ∅ | ∅ | ∅ | ∅ | doi:10.1128/CMR.00109-14 | ∅ | ∅ | ∅
12. Fumagalli, M. et al. . , 19(2), 199 212 | 2009 | "Widespread Balancing Selection and Pathogen-Driven Selection at Blood Group Antigen Genes" | Genome Research | ∅ | ∅ | ∅ | ∅ | doi:10.1101/gr.082768.108 | ∅ | ∅ | ∅

CROSS-REFERENCE INDEX

• L_2_02 — Population Genetics: ABO as model for allele frequency calculation
• Z_2_04 — Genetic Disorders: HDFN as genetic disease
• Z_1_04 — Gene Expression Regulation: Duffy promoter mutation silencing expression
• R_1_12 — History of Evolutionary Theory: Pathogen-driven selection maintaining blood group diversity
• L_4_02 — Mendel Inheritance: ABO as textbook Mendelian trait

Last verified: Mar 09, 2026 — All sources peer-reviewed or from established immunogenetics and hematology literature

Corrections

• Unregistered DOI removed — this entry carried 10.1016/S1521-6926(02)00086-7 (reassembled from a field-split fault). It returns 404 from doi.org itself, so it was never a registered identifier. A search on title, author, journal and year found no record that corroborated on all four, so no replacement could be verified. Rather than leave a link that fails or substitute a plausible-looking one, the identifier has been removed; the citation's author, title, journal, volume and year are unaffected and remain sufficient to locate the work. Corpus hygiene campaign, Phase 4, 2026-07-29.